Antisense technology: an overview and prospectus.
Journal
Nature reviews. Drug discovery
ISSN: 1474-1784
Titre abrégé: Nat Rev Drug Discov
Pays: England
ID NLM: 101124171
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
accepted:
08
02
2021
pubmed:
26
3
2021
medline:
11
8
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
Antisense technology is now beginning to deliver on its promise to treat diseases by targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing four chemical classes, two mechanisms of action and four routes of administration have been approved for commercial use, including the first RNA-targeted drug to be a major commercial success, nusinersen. Although all the approved drugs are for use in patients with rare diseases, many of the ASOs in late- and middle-stage clinical development are intended to treat patients with very common diseases. ASOs in development are showing substantial improvements in potency and performance based on advances in medicinal chemistry, understanding of molecular mechanisms and targeted delivery. Moreover, the ASOs in development include additional mechanisms of action and routes of administration such as aerosol and oral formulations. Here, we describe the key technological advances that have enabled this progress and discuss recent clinical trials that illustrate the impact of these advances on the performance of ASOs in a wide range of therapeutic applications. We also consider strategic issues such as target selection and provide perspectives on the future of the field.
Identifiants
pubmed: 33762737
doi: 10.1038/s41573-021-00162-z
pii: 10.1038/s41573-021-00162-z
doi:
Substances chimiques
Oligonucleotides, Antisense
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-453Références
Zamecnik, P. C. & Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75, 280–284 (1978). This paper introduces the concept of ASO therapeutics.
pubmed: 75545
Stephenson, M. L. & Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl Acad. Sci. USA 75, 285–288 (1978).
pubmed: 75546
Crooke, S. T. Progress toward oligonucleotide therapeutics: pharmacodynamic properties. FASEB J. 7, 533–539 (1993).
pubmed: 7682523
Crooke, S. T. Antisense therapeutics. Biotechnol. Genet. Eng. Rev. 15, 121–157 (1998).
pubmed: 9573607
Crooke, S. T., Vickers, T. A., Lima, W. F. & Wu, H.-J. in Antisense Drug Technology: Principles, Strategies, and Applications (ed. Crooke, S. T.) 3–46 (CRC, 2008).
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F. & Krainer, A. R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 5, e73 (2007). This paper shows how occupancy-based ASOs that do not mediate degradation by RNase H1 can be used to modulate splicing of a gene coding for the protein SMN, providing the basis for the successful development of a strategy to treat patients with SMA.
pubmed: 17355180
pmcid: 17355180
Crooke, S. T., Witztum, J. L., Bennett, C. F. & Baker, B. F. RNA-targeted therapeutics. Cell Metab. 27, 714–739 (2018). This is a comprehensive review of antisense approaches targeting RNA for the treatment of various diseases.
pubmed: 29617640
Foster, D. J. et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol. Ther. 26, 708–717 (2018).
pubmed: 29456020
pmcid: 5910670
Setten, R. L., Rossi, J. J. & Han, S. P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 18, 421–446 (2019). This review provides a comprehensive description of advances and outstanding questions with the application of siRNAs as therapeutics.
pubmed: 30846871
Swayze, E. E. & Bhat, B. in Antisense Drug Technology: Principles, Strategies, and Applications Ch. 6 (ed. Crooke, S. T.) 143–182 (CRC, 2008).
Monia, B. P. et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514–14522 (1993). This paper presents the initial pharmacological characterization of PS 2′-MOE chimeric ASOs.
pubmed: 8390996
Yu, D. et al. Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. Bioorg. Med. Chem. 4, 1685–1692 (1996).
pubmed: 8931938
Kurreck, J., Wyszko, E., Gillen, C. & Erdmann, V. A. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911–1918 (2002).
pubmed: 11972327
pmcid: 113840
Wan, W. B. & Seth, P. P. The medicinal chemistry of therapeutic oligonucleotides. J. Med. Chem. 59, 9645–9667 (2016).
pubmed: 27434100
Freier, S. M. & Altmann, K. H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429–4443 (1997).
pubmed: 9358149
pmcid: 147101
Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51 (2015).
pubmed: 25666165
Bennett, C. F. Therapeutic antisense oligonucleotides are coming of age. Annu. Rev. Med. 70, 307–321 (2019).
pubmed: 30691367
pmcid: 30691367
Sands, H. et al. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 932–943 (1994).
pubmed: 8190109
Geary, R. S. et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890–897 (2001).
pubmed: 11181921
Liang, X. H., Sun, H., Shen, W. & Crooke, S. T. Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res. 43, 2927–2945 (2015). This is the first paper to systematically identify cellular proteins to which PS ASOs bind.
pubmed: 25712094
pmcid: 4357732
Wang, S., Sun, H., Tanowitz, M., Liang, X. H. & Crooke, S. T. Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides. Nucleic Acids Res. 44, 7314–7330 (2016).
pubmed: 27378781
pmcid: 5009748
Miller, C. M. et al. Stabilin-1 and stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res. 44, 2782–2794 (2016).
pubmed: 26908652
pmcid: 4824115
Wang, S. et al. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res. 46, 3579–3594 (2018).
pubmed: 29514240
pmcid: 5909429
Liang, X. H. et al. Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes. Nucleic Acids Res. 48, 1372–1391 (2020). This is one of a series of papers describing protein-mediated PS ASO intracellular trafficking and endosomal release.
pubmed: 31840180
Crooke, S. T., Vickers, T. A. & Liang, X. H. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 48, 5235–5253 (2020). This paper reviews the proteins to which PS ASOs bind and the effects of those interactions on the behaviours of both PS ASOs and the proteins.
pubmed: 32356888
pmcid: 7261153
Iversen, P. L. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3, 235–238 (2001).
pubmed: 11497346
Iversen, P. L. in Antisense Drug Technology: Principles, Strategies, and Applications (ed. Crooke, S. T.) 565–582 (CRC, 2008).
Aartsma-Rus, A. & Corey, D. R. The 10th oligonucleotide therapy approved: golodirsen for duchenne muscular dystrophy. Nucleic Acid. Ther. 30, 67–70 (2020).
pubmed: 32043902
pmcid: 7133412
Dhillon, S. Viltolarsen: first approval. Drugs 80, 1027–1031 (2020).
pubmed: 32519222
Monia, B. P., Johnston, J. F., Sasmor, H. & Cummins, L. L. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem. 271, 14533–14540 (1996).
pubmed: 8662854
Prakash, T. P. et al. Comparing in vitro and in vivo activity of 2′-O-[2-(methylamino)-2-oxoethyl]- and 2′-O-methoxyethyl-modified antisense oligonucleotides. J. Med. Chem. 51, 2766–2776 (2008).
pubmed: 18399648
Stix, G. Shutting down a gene. Antisense drug wins approval. Sci. Am. 279, 46–50 (1998).
pubmed: 9841380
Mansoor, M. & Melendez, A. J. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul. Syst. Biol 2, 275–295 (2008).
Monia, B. P. First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des. 12, 327–339 (1997).
pubmed: 9236850
Henry, S. P. et al. in Antisense Drug Technology-Principles, Strategies, and Applications (ed. Crooke, S. T.) 327–364 (CRC, 2008).
Hong, D. et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci. Transl Med. 7, 314ra185 (2015).
pubmed: 26582900
pmcid: 5279222
Chowdhury, S. et al. A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR). Eur. J. Cancer 69, S145 (2016).
Seth, P. P. et al. Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symp. Ser. 52, 553–554 (2008). This paper introduces the 2′-cEt modification.
Simoes-Wust, A. P. et al. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides 14, 199–209 (2004).
pubmed: 15625915
Sugo, T. et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J. Control. Release 237, 1–13 (2016).
pubmed: 27369865
Ammala, C. et al. Targeted delivery of antisense oligonucleotides to pancreatic beta-cells. Sci. Adv. 4, eaat3386 (2018). This paper shows that ASOs can be specifically delivered into pancreatic β-cells through GLP1 conjugation in vitro and in vivo.
pubmed: 30345352
pmcid: 6192685
Ostergaard, M. E. et al. Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Res. 47, 6045–6058 (2019).
pubmed: 31076766
pmcid: 31076766
Prakash, T. P. et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796–8807 (2014). This paper shows that GalNAc conjugation dramatically enhances ASO potency in vivo by selective targeting to hepatocytes through the cell-surface asialoglycoprotein receptor.
pubmed: 24992960
pmcid: 4117763
Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961 (2014). This paper shows that GalNAc conjugation enables siRNA delivery to the liver through interactions with the GalNAc asialoglycoprotein receptor, which is highly expressed on hepatocytes.
pubmed: 25434769
Shen, W. et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat. Biotechnol. 37, 640–650 (2019). This study unveils a detailed toxic mechanism mediated by PS-ASO–protein interactions and how straightforward chemical modification can mitigate toxicity.
pubmed: 31036929
Migawa, M. T. et al. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Res. 47, 5465–5479 (2019).
pubmed: 31034558
pmcid: 6582325
Crooke, S. T., Seth, P. P., Vickers, T. A. & Liang, X. H. The interaction of phosphorothioate-containing RNA targeted drugs with proteins is a critical determinant of the therapeutic effects of these agents. J. Am. Chem. Soc. 142, 14754–14771 (2020).
pubmed: 32786803
Crooke, S. T., Liang, X.-H., Crooke, R. M., Baker, B. F. & Geary, R. S. Antisense drug discovery and development technology considered in a pharmacological context. Biochem. Pharmacol. https://doi.org/10.1016/j.bcp.2020.114196 (2020). This paper provides a comprehensive review of RNA-targeted drug discovery with a focus on molecular mechanisms of action, cellular pharmacokinetic and toxicological effects, including a discussion of the mechanistic differences between RNase-H1- and AGO2-induced cleavage mediated by ASOs.
doi: 10.1016/j.bcp.2020.114196
pubmed: 32800852
Lima, W. F. et al. Single-stranded siRNAs activate RNAi in animals. Cell 150, 883–894 (2012). This paper shows that chemically modified single-stranded oligonucleotides can act as siRNAs and activate the RNA-induced silencing complex (RISC) pathway in vitro and in vivo.
pubmed: 22939618
Ward, A. J., Norrbom, M., Chun, S., Bennett, C. F. & Rigo, F. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Nucleic Acids Res. 42, 5871–5879 (2014).
pubmed: 24589581
pmcid: 4027159
Liang, X. H., Nichols, J. G., Hsu, C. W., Vickers, T. A. & Crooke, S. T. mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway. Nucleic Acids Res. 47, 6900–6916 (2019). This is one of a series of papers describing the designs of PS ASOs that can cause target reduction via non-RNase-H1 mechanisms.
pubmed: 31165876
pmcid: 6649848
Melton, D. A. Injected anti-sense RNAs specifically block messenger RNA translation in vivo. Proc. Natl Acad. Sci. USA 82, 144–148 (1985).
pubmed: 3855537
Baker, B. F. et al. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994–12000 (1997).
pubmed: 9115264
Iversen, P. L., Arora, V., Acker, A. J., Mason, D. H. & Devi, G. R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin. Cancer Res. 9, 2510–2519 (2003).
pubmed: 12855625
Baker, B. F. et al. Oligonucleotide-europium complex conjugate designed to cleave the 5′ cap structure of the ICAM-1 transcript potentiates antisense activity in cells. Nucleic Acids Res. 27, 1547–1551 (1999).
pubmed: 10037819
pmcid: 148351
Vickers, T. A., Wyatt, J. R., Burckin, T., Bennett, C. F. & Freier, S. M. Fully modified 2′ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. 29, 1293–1299 (2001).
pubmed: 11238995
pmcid: 29745
Hodges, D. & Crooke, S. T. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol. Pharmacol. 48, 905–918 (1995). This is the first paper to explore the RNA sequence and structural features that determine the efficiency of ASO-induced alternative splicing.
pubmed: 7476922
Finkel, R. S. et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017). This paper reports a clinical trial showing that nusinersen, an ASO that modulates the splicing of SMN2, can safely improve motor neuron function in patients with SMA.
pubmed: 29091570
Charleston, J. S. et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 90, e2146–e2154 (2018).
pubmed: 29752304
Bennett, C. F., Krainer, A. R. & Cleveland, D. W. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu. Rev. Neurosci. 42, 385–406 (2019).
pubmed: 31283897
pmcid: 7427431
Darras, B. T. et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs 33, 919–932 (2019).
pubmed: 31420846
pmcid: 6776494
Orom, U. A., Kauppinen, S. & Lund, A. H. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372, 137–141 (2006).
pubmed: 16503100
De Santi, C. et al. Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells. Mol. Ther. 28, 1190–1199 (2020).
pubmed: 32059764
pmcid: 7132615
Stenvang, J., Petri, A., Lindow, M., Obad, S. & Kauppinen, S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 3, 1 (2012).
pubmed: 22230293
pmcid: 3306207
van der Ree, M. H. et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment. Pharmacol. Ther. 43, 102–113 (2016).
pubmed: 26503793
Liang, X.-H. et al. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat. Biotech. 34, 875–880 (2016). This paper shows that PS ASOs can be designed to selectively increase the translation of specific proteins.
Liang, X. H. et al. Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels. Nucleic Acids Res. 45, 9528–9546 (2017).
pubmed: 28934489
pmcid: 5766168
Huang, L. et al. Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations. Genome Biol. 19, 4 (2018).
pubmed: 29334995
pmcid: 5769327
Nomakuchi, T. T., Rigo, F., Aznarez, I. & Krainer, A. R. Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay. Nat. Biotechnol. 34, 164–166 (2016).
pubmed: 26655495
Li, L. C. et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl Acad. Sci. USA 103, 17337–17342 (2006).
pubmed: 17085592
Janowski, B. A. et al. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 3, 166–173 (2007).
pubmed: 17259978
Liang, X. H., Nichols, J. G., Sun, H. & Crooke, S. T. Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs. Nucleic Acids Res. 46, 293–313 (2018).
pubmed: 29165591
Frank, D. E. et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 94, e2270–e2282 (2020).
pubmed: 32139505
pmcid: 7357297
Cirak, S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378, 595–605 (2011).
pubmed: 21784508
pmcid: 3156980
Levin, A. A., Yu, R. Z. & Geary, R. S. in Antisense Drug Technology: Principles, Strategies, and Applications 2nd edn (ed. Crooke, S. T.) 183–216 (CRC, 2008). This paper establishes the basic principles related to various adverse effects of PS ASOs.
Gaus, H. J. et al. Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay. Nucleic Acids Res. 47, 1110–1122 (2019).
pubmed: 30566688
Geary, R. S., Baker, B. F. & Crooke, S. T. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin. Pharmacokinet. 54, 133–146 (2015).
pubmed: 25559341
pmcid: 4305106
Geary, R. S., Yu, R. Z., Siwkoswki, A., and Levin, A. A. in Antisense Drug Technology: Principles, Strategies, and Applications 2nd edn (ed. Crooke, S. T.) 305–326 (CRC, 2008).
Graham, M. J. et al. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem. Pharmacol. 62, 297–306 (2001). This is the first paper to define the sub-organ pharmacokinetics of PS ASOs and is also the first systematic sub-organ pharmacokinetic study of any drug.
pubmed: 11434902
Crooke, S. T. et al. Integrated safety assessment of 2′-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol. Ther. 24, 1771–1782 (2016). This is the first publication of an integrated safety database for a chemical class of PS ASOs.
pubmed: 27357629
pmcid: 5112040
Crooke, S. T. et al. The effects of 2′-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid. Ther. 27, 121–129 (2017).
pubmed: 28145801
pmcid: 5467133
Crooke, S. T. et al. The effects of 2′-O-methoxyethyl oligonucleotides on renal function in humans. Nucleic Acid. Ther. 28, 10–22 (2018).
pubmed: 29185862
pmcid: 5790433
Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22–31 (2018). This paper reports a clinical trial showing that inotersen improved the course of neurological disease and quality of life in patients with hATTR.
pubmed: 29972757
Witztum, J. L. et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N. Engl. J. Med. 381, 531–542 (2019). This paper reports a clinical trial showing that volanesorsen lowered triglyceride levels to <750 mg dl
pubmed: 31390500
Hong, D. S. et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 17, 6582–6591 (2011).
pubmed: 21831956
pmcid: 5036398
Crooke, S. T. et al. Integrated assessment of the clinical performance of GalNAc3-conjugated 2′-O-methoxyethyl chimeric antisense oligonucleotides: I. human volunteer experience. Nucleic Acid. Ther. 29, 16–32 (2019).
pubmed: 30570431
pmcid: 6386089
Gouni-Berthold, I. Significant quality of life improvement observed in a patient with FCS associated with a marked reduction in triglycerides. J. Endocr. Soc. 4, bvz035 (2020).
pubmed: 32083235
Yuen, M. F. et al. Results after 12 weeks treatment of multiple doses of GSK3389404 in chronic hepatitis B (CHB) subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study. Hepatology 70, 433A–434A (2019).
Tsimikas, S. et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382, 244–255 (2020). This paper describes the results of a large phase IIb study in patients with prior cardiovascular events treated with pelacarsen, a PS 2′-MOE chimeric ASO that reduces levels of Lp(a).
pubmed: 31893580
Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685–1694 (2013).
pubmed: 23534542
Hagedorn, P. H. et al. Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov. Today 23, 101–114 (2018).
pubmed: 28988994
Vickers, T. A., Rahdar, M., Prakash, T. P. & Crooke, S. T. Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1. Nucleic Acids Res. 47, 10865–10880 (2019).
pubmed: 31495875
pmcid: 6846478
Kim, Y. et al. Enhanced potency of GalNAc-conjugated antisense oligonucleotides in hepatocellular cancer models. Mol. Ther. 27, 1547–1557 (2019).
pubmed: 31303442
pmcid: 6731179
Tillman, L. G., Geary, R. S. & Hardee, G. E. Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97, 225–236 (2008).
pubmed: 17721945
Yu, R. Z. et al. Investigation of oral delivery of GalNac3 conjugated antisense oligonucleotides in rats. in DIA/FDA Oligonucleotide-Based Therapeutics Conference (FDA and DIA, 2019). This study reports that a PS MOE GalNAc-conjugated ASO can be delivered orally.
Gennemark, P. et al. Abstract 13307: an oral antisense oligonucleotide for PCSK9 inhibition in humans. Circulation 142, A13307–A13307 (2020).
Chiriboga, C. A. et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86, 890–897 (2016).
pubmed: 26865511
pmcid: 4782111
Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017–3026 (2016).
pubmed: 27939059
Mercuri, E. et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625–635 (2018).
pubmed: 29443664
Karras, J. G. et al. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am. J. Respir. Cell Mol. Biol. 36, 276–285 (2007).
pubmed: 16990616
Zhao, C. et al. Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits alpha, beta, and gamma improves cystic fibrosis-like disease in mice. J. Cyst. Fibros. 18, 334–341 (2019).
pubmed: 30100257
Crosby, J. R. et al. Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice. J. Cyst. Fibros. 16, 671–680 (2017).
pubmed: 28539224
Miner, P., Wedel, M., Bane, B. & Bradley, J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment. Pharmacol. Ther. 19, 281–286 (2004).
pubmed: 14984374
Greuter, T. & Rogler, G. Alicaforsen in the treatment of pouchitis. Immunotherapy 9, 1143–1152 (2017).
pubmed: 29067882
Grillone, L. R. & Lanz, R. Fomivirsen. Drugs Today 37, 245–255 (2001).
Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).
pubmed: 7813012
Montes, J. et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve 60, 409–414 (2019).
pubmed: 31298747
pmcid: 6771553
De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul. Disord. 29, 842–856 (2019).
pubmed: 31704158
pmcid: 7127286
Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993).
Miller, T. et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109–119 (2020).
Cudkowicz, M. et al. Tofersen, a SOD1 antisense oligonucleotide in participants with ALS – results from a multiple dose study (657). Neurology 94 (Suppl. 15), 657 (2020).
Hummerich, H. et al. Distribution of trinucleotide repeat sequences across a 2 Mbp region containing the Huntington’s disease gene. Hum. Mol. Genet. 3, 73–78 (1994).
pubmed: 8162055
Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380, 2307–2316 (2019).
pubmed: 31059641
Panzara, M. Stereopure nucleic acid therapies in development for the treatment of genetic neurological diseases. Neurotherapeutics 14, 821–822 (2017).
Kesselheim, A. S. & Avorn, J. Approving a problematic muscular dystrophy drug: implications for FDA policy. JAMA 316, 2357–2358 (2016).
pubmed: 27775756
Clemens, P. R. et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 77, 982–991 (2020).
pubmed: 32453377
Wagner, K. et al. O.28. Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial. Neuromuscul. Disord. 29, S124 (2019).
Flora, G. D. & Nayak, M. K. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr. Pharm. Des. 25, 4063–4084 (2019).
pubmed: 31553287
Goldberg, A. C. & Schonfeld, G. Effects of diet on lipoprotein metabolism. Annu. Rev. Nutr. 5, 195–212 (1985).
pubmed: 3896268
Castro-Barquero, S., Ruiz-León, A. M., Sierra-Pérez, M., Estruch, R. & Casas, R. Dietary strategies for metabolic syndrome: a comprehensive review. Nutrients 12, 2983 (2020).
pmcid: 7600579
Ying, H., Wang, J., Shen, Z., Wang, M. & Zhou, B. Impact of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering medicines on cognitive function: a systematic review and meta-analysis. Cardiovasc. Drugs Ther. 35, 153–166 (2020).
pubmed: 32770521
Raal, F. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998–1006 (2010). This paper presents clinical trial results showing that mipomersen can significantly lower LDL cholesterol levels in patients with HoFH.
pubmed: 20227758
Santos, R. D., Raal, F. J., Donovan, J. M. & Cromwell, W. C. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J. Clin. Lipidol. 9, 201–209 (2015).
pubmed: 25911076
Sobati, S. et al. PCSK9: a key target for the treatment of cardiovascular disease (CVD). Adv. Pharm. Bull. 10, 502–511 (2020).
pubmed: 33062601
pmcid: 7539318
Visser, M. E., Witztum, J. L., Stroes, E. S. & Kastelein, J. J. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 33, 1451–1458 (2012).
pubmed: 22634577
Schmitz, J. & Gouni-Berthold, I. Anti-PCSK9 antibodies: a new era in the treatment of dyslipidemia. Curr. Pharm. Des. 23, 1484–1494 (2017).
pubmed: 28137217
German, C. A. & Shapiro, M. D. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs 34, 1–9 (2020).
pubmed: 31782112
Kosmas, C. E. et al. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential. Ther. Clin. Risk Manag. 16, 1031–1037 (2020).
pubmed: 33149595
pmcid: 7604242
Tsimikas, S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J. Am. Coll. Cardiol. 69, 692–711 (2017).
pubmed: 28183512
Chait, A. & Eckel, R. H. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann. Intern. Med. 170, 626–634 (2019).
pubmed: 31035285
Varbo, A. et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 61, 427–436 (2013).
pubmed: 23265341
Johansen, C. T., Kathiresan, S. & Hegele, R. A. Genetic determinants of plasma triglycerides. J. Lipid Res. 52, 189–206 (2011).
pubmed: 21041806
pmcid: 3023540
Digenio, A. et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care 39, 1408–1415 (2016).
pubmed: 27271183
Milonas, D. & Tziomalos, K. Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia — spotlight on volanesorsen. Expert Opin. Investig. Drugs 28, 389–394 (2019).
pubmed: 30753100
Tardif, J.-C. Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins. Presented at the European Society of Cardiology Congress (2020).
Loomba, R. et al. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 5, 829–838 (2020).
pubmed: 32553151
Buller, H. R., Gailani, D. & Weitz, J. I. Factor XI antisense oligonucleotide for venous thrombosis. N. Engl. J. Med. 372, 1672 (2015).
pubmed: 25901434
Buller, H. R. et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 372, 232–240 (2015).
pubmed: 25482425
Cideciyan, A. V. et al. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. Nat. Med. 25, 225–228 (2019).
pubmed: 30559420
MacLeod, A. R. & Crooke, S. T. RNA therapeutics in oncology: advances, challenges, and future directions. J. Clin. Pharmacol. 57 (Suppl. 10), S43–S59 (2017).
pubmed: 28921648
Reilley, M. J. et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J. Immunother. Cancer 6, 119 (2018).
pubmed: 30446007
pmcid: 6240242
Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A. & Croce, C. M. MicroRNA expression and function in cancer. Trends Mol. Med. 12, 580–587 (2006).
pubmed: 17071139
Anastasiadou, E. et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo. Clin. Cancer Res. 27, 1139–1149 (2020).
pubmed: 33208342
Querfeld, C. et al. Phase 1 study of the safety and efficacy of MRG-106, a synthetic inhibitor of microRNA-155, in CTCL patients. Blood 130 (Suppl. 1), 820 (2017).
James, A. M. et al. SOLAR: a phase 2, global, randomized, active comparator study to investigate the efficacy and safety of cobomarsen in subjects with mycosis fungoides (MF). Hemato. Oncol. 37, 562–563 (2019).
Fuertes, T., Ramiro, A. R. & de Yebenes, V. G. miRNA-based therapies in B cell non-hodgkin lymphoma. Trends Immunol. 41, 932–947 (2020).
pubmed: 32888820
Yuen, M. F. et al. Phase 2a, randomized, double-blind, placebocontrolled study of an antisense inhibitor (ISIS 505358) in treatment-naïve chronic hepatitis B (CHB) patients: safety and antiviral efficacy. Hepatology 70, 437A–438A (2019).
Gane, E. J. et al. Interim results of a phase 1 study of RO7062931, a novel liver-targeted single-stranded oligonucleotide (SSO) with locked nucleic acid (LNA) that targets HBV transcripts. Hepatology 70, 436A (2019).
Feng, S. et al. Liver targeted single stranded (SSO) oligonucleotide RO7062931 is safe and well tolerated in Chinese healthy volunteers (HVs) with similar pharmacokinetic profile to non-Chinese HVs. Hepatol. Int. https://doi.org/10.1007/s12072-020-10030-4 (2020).
Gregory, S. A. & Karras, J. G. in Antisense Drug Technology: Principles, Strategies, and Applications 2nd edn (ed. Crooke, S. T.) 665–697 (CRC, 2008).
Sermet-Gaudelus, I. et al. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis. J. Cyst. Fibros. 18, 536–542 (2019).
pubmed: 30467074
Drevinek, P. et al. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis. J. Cyst. Fibros. 19, 99–107 (2020).
pubmed: 31182369
Zamecnik, P. C., Raychowdhury, M. K., Tabatadze, D. R. & Cantiello, H. F. Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. Proc. Natl Acad. Sci. USA 101, 8150–8155 (2004).
pubmed: 15148387
Beumer, W. et al. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis. PLoS ONE 14, e0219182 (2019).
pubmed: 31251792
pmcid: 6599119
Bell, D. et al. Safety, tolerability, and target engagement demonstrated with inhaled αENaC antisense oligonucleotide (ION-827359) in a phase 1 healthy volunteer study. Presented at the North American Cystic Fibrosis Conference (2020).
Michaels, W. E., Bridges, R. J. & Hastings, M. L. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells. Nucleic Acids Res. 48, 7454–7467 (2020).
pubmed: 32520327
pmcid: 7367209
Gertz, M. A. et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Rev. Clin. Pharmacol. 12, 701–711 (2019).
pubmed: 31268366
Luigetti, M., Romano, A., Di Paolantonio, A., Bisogni, G. & Sabatelli, M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther. Clin. Risk Manag. 16, 109–123 (2020).
pubmed: 32110029
pmcid: 7041433
Narayanan, P. et al. Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia. Nucleic Acid Ther. 30, 94–103 (2020).
pubmed: 32043907
Brannagan, T. H. et al. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur. J. Neurol. 27, 1374–1381 (2020).
pubmed: 32343462
pmcid: 7496583
Viney, N. J. et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 8, 652–661 (2020).
pubmed: 33283485
pmcid: 7835591
Lima, W., Wu, H. & Crooke, S. T. in Antisense Drug Technology: Principles, Strategies, and Applications 2nd edn (ed. Crooke, S. T.) 47–74 (CRC, 2008). This paper summarizes the properties of the human RNase H enzyme.
Manoharan, M. & Rajeev, K. G. in Antisense Drug Technology: Principles, Strategies, and Applications 2nd edn (ed. Crooke, S. T.) 437–464 (CRC, 2008).
Manoharan, M. et al. Unique gene-silencing and structural properties of 2′-fluoro-modified siRNAs. Angew. Chem. Int. Ed. Engl. 50, 2284–2288 (2011).
pubmed: 21351337
pmcid: 3516925
Shukla, S., Sumaria, C. S. & Pradeepkumar, P. I. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 5, 328–349 (2010).
pubmed: 20043313
Sigova, A. & Zamore, O. D. in Antisense Drug Technology: Principles, Strategies, and Applications 2nd edn (ed. Crooke, S. T.) 75–88 (CRC, 2008).
Chernikov, I. V., Vlassov, V. V. & Chernolovskaya, E. L. Current development of siRNA bioconjugates: from research to the clinic. Front. Pharmacol. 10, 444 (2019).
pubmed: 31105570
pmcid: 6498891
Tang, X. et al. Therapeutic prospects of mRNA-based gene therapy for glioblastoma. Front. Oncol. 9, 1208 (2019).
pubmed: 31781503
pmcid: 6857656
Anguela, X. M. & High, K. A. Entering the modern era of gene therapy. Annu. Rev. Med. 70, 273–288 (2019).
pubmed: 30477394
Lima, W. F., De Hoyos, C. L., Liang, X. H. & Crooke, S. T. RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery. Nucleic Acids Res. 44, 3351–3363 (2016).
pubmed: 26843429
pmcid: 4838368
Vickers, T. A. et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108–7118 (2003). This study shows that the activities of ASOs and siRNAs are comparable in cells.
pubmed: 12500975
Vickers, T. A. et al. Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 ‘Slicer’ independent and can be mediated by Ago1. Nucleic Acids Res. 37, 6927–6941 (2009).
pubmed: 19767612
pmcid: 2777430
Lima, W. F., Vickers, T. A., Nichols, J., Li, C. & Crooke, S. T. Defining the factors that contribute to on-target specificity of antisense oligonucleotides. PLoS ONE 9, e101752 (2014). This paper characterizes the features of RNAs and ASOs that are associated with off-target cleavage.
pubmed: 25072142
pmcid: 4114480
Vickers, T. A. & Crooke, S. T. Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PLoS ONE 9, e108625 (2014).
pubmed: 25299183
pmcid: 4191969
Khan, A. A. et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol. 27, 549–555 (2009).
pubmed: 19465925
pmcid: 2782465
Liang, X. H., Hart, C. E. & Crooke, S. T. Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. Biochim. Biophys. Acta 1829, 455–468 (2013).
pubmed: 23403288
Liang, X. H. & Crooke, S. T. RNA helicase A is not required for RISC activity. Biochim. Biophys. Acta 1829, 1092–1101 (2013).
pubmed: 23895878
Michlewski, G. & Caceres, J. F. Post-transcriptional control of miRNA biogenesis. RNA 25, 1–16 (2019).
pubmed: 30333195
pmcid: 6298569
Springer, A. D. & Dowdy, S. F. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid. Ther. 28, 109–118 (2018).
pubmed: 29792572
pmcid: 5994659
Gale, J. D. et al. A placebo-controlled study of PF-06473871 (anti-connective tissue growth factor antisense oligonucleotide) in reducing hypertrophic skin scarring. Plast. Reconstr. Surg. Glob. Open 6, e1861 (2018).
pubmed: 30349773
pmcid: 6191237
Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133, 467–474 (2002).
Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133, 484–498 (2002).
Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am. J. Ophthalmol. 133, 475–483 (2002).
Duell, P. B. & Jialal, I. Modern management of familial hypercholesterolemia. Metab. Syndr. Relat. Disord. 14, 463–467 (2016).
pubmed: 27797643
Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637–647 (2013).
pubmed: 23907995
Raal, F. J. et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124, 2202–2207 (2011).
pubmed: 21986285
Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435–442 (2013).
pubmed: 23541756
pmcid: 3712285
Goemans, N. M. et al. Long-term efficacy, safety, and pharmacokinetics of drisapersen in duchenne muscular dystrophy: results from an open-label extension study. PLoS ONE 11, e0161955 (2016).
pubmed: 27588424
pmcid: 5010191
Voit, T. et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 13, 987–996 (2014).
pubmed: 25209738
Mignon, L. et al. ISIS-DMPKRx in healthy volunteers: a placebo-controlled, randomized, single ascending-dose phase 1 study (P3.166). Neurology 86 (Suppl. 16), P3.166 (2016).
Gaudet, D. et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur. Heart J. 41, 3936–3945 (2020).
pubmed: 32860031
pmcid: 7750927
Graham, M. J. et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N. Engl. J. Med. 377, 222–232 (2017).
pubmed: 28538111
Alexander, V. J. et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur. Heart J. 40, 2785–2796 (2019).
pubmed: 31329855
pmcid: 6736334
Grossman, T. R. et al. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide. Mol. Vis. 23, 561–571 (2017).
pubmed: 28855795
pmcid: 5563462
Täubel, J. et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 42, 178–188 (2020).
pmcid: 7954267
Morgan, E. S. et al. Antisense inhibition of glucagon receptor by IONIS-GCGRRx improves type 2 diabetes without increase in hepatic glycogen content in patients with type 2 diabetes on stable metformin therapy. Diabetes Care 42, 585–593 (2019).
pubmed: 30765435
Trainer, P. J. et al. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. Eur. J. Endocrinol. 179, 97–108 (2018).
pubmed: 29789410
pmcid: 6063983
Digenio, A. et al. Antisense inhibition of protein tyrosine phosphatase 1B with IONIS-PTP-1BRx improves insulin sensitivity and reduces weight in overweight patients with type 2 diabetes. Diabetes Care 41, 807–814 (2018).
pubmed: 29439147
Bhanot, S. et al. ISIS-GCCRRX, a novel glucocorticoid (GC) receptor antisense drug reduces cholesterol and triglycerides and attenuates dexamethasone induced hepatic insulin resistance without systemic GC antagonism in normal subjects. Diabetologia 56, S282 (2013).
Pfeiffer, N. et al. First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-beta2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS ONE 12, e0188899 (2017).
pubmed: 29190672
pmcid: 5708654
Chi, K. N. et al. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann. Oncol. 27, 1116–1122 (2016).
pubmed: 27022067
Saad, F. et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17, 5765–5773 (2011).
pubmed: 21788353
Bianchini, D. et al. First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br. J. Cancer 109, 2579–2586 (2013).
pubmed: 24169353
pmcid: 3833213
van der Ree, M. H. et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet 18, 709–717 (2017).
Limmroth, V., Barkhof, F., Desem, N., Diamond, M. P. & Tachas, G. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology 83, 1780–1788 (2014).
pubmed: 25239835
pmcid: 4240428
Sands, B. E. et al. Mongersen (GED-0301) for active Crohn’s disease: results of a phase 3 study. Am. J. Gastroenterol. 115, 738–745 (2020).
pubmed: 31850931
Monteleone, G. & Pallone, F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N. Engl. J. Med. 372, 2461 (2015).
pubmed: 26083213
Sewell, K. L. et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther. 303, 1334–1343 (2002).
pubmed: 12438559
Cohn, D. M. et al. Antisense inhibition of prekallikrein to control hereditary angioedema. N. Engl. J. Med. 383, 1242–1247 (2020).
pubmed: 32877578
Liu, H. et al. Targeting the IL-17 receptor using liposomal spherical nucleic acids as topical therapy for psoriasis. J. Invest. Dermatol. 140, 435–444.e434 (2020).
pubmed: 31421125
Ferrone, J. D. et al. IONIS-PKKRx a novel antisense inhibitor of prekallikrein and bradykinin production. Nucleic Acid. Ther. 29, 82–91 (2019).
pubmed: 30817230
pmcid: 6461157
van Meer, L. et al. Renal effects of antisense-mediated inhibition of SGLT2. J. Pharmacol. Exp. Ther. 359, 280–289 (2016).
pubmed: 27605629
Matsui, M. & Corey, D. R. Non-coding RNAs as drug targets. Nat. Rev. Drug Discov. 16, 167–179 (2017).
pubmed: 27444227
Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351–379 (2010).
pubmed: 20533884
Gibson, N. W. Engineered microRNA therapeutics. J. R. Coll. Physicians Edinb. 44, 196–200 (2014).
pubmed: 25318394
Chakraborty, C., Sharma, A. R., Sharma, G. & Lee, S.-S. Therapeutic advances of miRNAs: a preclinical and clinical update. J. Adv. Res. 28, 127–138 (2020).
pubmed: 33364050
pmcid: 7753224
Wang, Z. The principles of MiRNA-masking antisense oligonucleotides technology. Methods Mol. Biol. 676, 43–49 (2011).
pubmed: 20931388
Eckstein, F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid. Drug Dev. 10, 117–121 (2000).
pubmed: 10805163
Oka, N., Wada, T. & Saigo, K. An oxazaphospholidine approach for the stereocontrolled synthesis of oligonucleoside phosphorothioates. J. Am. Chem. Soc. 125, 8307–8317 (2003).
pubmed: 12837103
Wan, W. B. et al. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res. 42, 13456–13468 (2014).
pubmed: 25398895
pmcid: 4267618
Ostergaard, M. E. et al. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Res. 48, 1691–1700 (2020).
pubmed: 31980820
pmcid: 7038945
Lee, R. G., Crosby, J., Baker, B. F., Graham, M. J. & Crooke, R. M. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J. Cardiovasc. Transl. Res. 6, 969–980 (2013).
pubmed: 23856914
pmcid: 3838598